Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

Women with the BRCA gene mutations have a 60 to 80 percent chance of developing /topics/Breast_Cancer" class="cnnInlineTopic">breast cancer-- at least five times higher than the general population -- ...

Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched ...

Here's what went down Thursday, January 1, 2026 on Beyond the Gates when Nicole's housekeeper got a name, Kat went against ...

It might feel like your world stops after receiving a diagnosis of breast or ovarian cancer. Even in that mental and emotional fog, there are several next steps to consider. Coming up with a treatment ...

An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...